ArticleTranslational cancer research2025
Ubiquitin-conjugating enzyme E2S serves as a prognostic marker for skin cutaneous melanoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The UBE2/E2 ubiquitin-conjugating enzyme family at the interface of tumor biology and antitumor immunity: mechanisms, biomarkers, and therapeutic opportunities.Frontiers in immunology · 2026Review
- UBE2S emerges as a key driver in an NK cell-based prognostic model for clear cell renal cell carcinoma.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study investigates the expression of ubiquitin-conjugating enzyme E2S (UBE2S) as a significant prognostic marker for skin cutaneous melanoma (SKCM) and its association with the tumor microenvironment (TME). The research aimed to advance precision oncology by identifying novel therapeutic targets for SKCM. Methods: UBE2S expression in normal skin and SKCM tissues was analyzed using Sangerbox, Gene Expression Profiling Interactive Analysis 2 (GEPIA2), and DiSignAtlas databases. Its relationship with SKCM prognosis was examined through GEPIA2, Sangerbox, Ualcan, and TISIDB. The Human Protein Atlas (HPA) database assessed UBE2S protein expression and localization in cancerous and adjacent tissues, normal skin single-cell subgroups, and various cell lines. The CellTracer database explored UBE2S expression and cell differentiation in SKCM single-cell subgroups. CancerSEA and CellTracer databases were utilized to explore UBE2S's role in SKCM single-cell analysis, while TISIDB examined its correlation with the TME. Results: Data from various databases showed significantly higher UBE2S messenger RNA (mRNA) and protein levels in cancer tissues compared to normal tissues. UBE2S, mainly found on the cell membrane, is linked to poor patient prognosis (P<0.05). UBE2S was highly expressed in normal skin, SKCM immune cells, and non-immune cell subpopulations, with a strong correlation to immune-related indicators in the SKCM TME (P<0.001). The A-431 and SK-MEL-30 cell lines ranked 7th and 12th in UBE2S expression among all cell lines. UBE2S expression was also positively linked to proliferation, invasion, metastasis, cell cycle, and quiescence (P<0.05). Conclusions: UBE2S has the potential to serve as a prognostic biomarker for SKCM, demonstrating a strong correlation with cellular infiltration within the SKCM TME and the functional status of individual cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.